脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)活性蛋白
Active Phospholipase A2 Group VII (LpPLA2)
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
- 編號APA867Ra61
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)7.6
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1920 ¥ 4800 ¥ 9600 ¥ 28800 ¥ 72000
- 欲了解實(shí)際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
活性實(shí)驗(yàn)
PLA2G-VII which is also known as Lp-PLA2, is a plasma enzyme bound to lipoproteins: 80% bound to LDL, 15%-20% to HDL, and the remainder to VLDL. It is produced in major by mature macrophages and activated platelets. In contrast to other classical sPLA2s, PLA2G-VII has poor specificity toward Sn-2 long chain fatty acids, unless heavily oxidized, and undergoes the catalysis of its substrates in the aqueous phase rather than at the interfacial surface of lipids. Thus, it has high specificity for water-soluble phospholipids in plasma including oxidatively-modified phospholipids and platelet-activating factor (PAF). Because of the latter activity, it is also known as PAF acetylhydrolase (PAF-AH). Lack of human PLA2G-VII is related to a higher risk for stroke and heart disease.The activity of recombinant rat PLA2G-VII was measured by its ability to cleave a colorimetric peptide substrate 1-O-hexadecyl-2-deoxy-2-thio-S-acetyl-sn-glyceryl-3-phosphorylcholine (2-Thio-PAF). The reaction was performed in 50 mM MES, 150 mM NaCl, 0.1 mg/mL BSA, pH 6.5 (Assay Buffer), initiated by addition 50 μL of various concentrations of PLA2G-VII (diluted by Assay Buffer) to 50 μL of 0.2 mM Substrate and 0.2 mM DTNB mixture. The final well serves as a negative control with no PLA2G-VII, replaced with 50 μL assay buffer. Then read absorbance at 405 nm in kinetic mode for 5 minutes. The specific activity of recombinant rat PLA2G-VII is 112.37 pmol/min/μg.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
APA867Ra61 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA867Ra61 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA867Ra01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA867Ra01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體 | WB; IHC; ICC; IP. |
SEA867Ra | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA867Ra | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Science & Sports | The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women [ScienceDirect: S0765159710000262] |
Metabolic Syndrome and Related Disorders | Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease [Wiley: source] |
34 | Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study [PubMed: 22240497] |
PLoS ONE | Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo [PubMed: PMC3759413] |
China Pharmacy | Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats [Source] |
Atherosclerosis | Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. [Pubmed: 23958269] |
Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Hindawi: 278063] |
Health | The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia [Scirp:Source] |
Biology Bulletin | In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood [Springer:Source] |
Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. [Pubmed:24397392] |
Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Pubmed:24818163] |
Metabolism. | Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes [Pubmed:25034387] |
J Am Heart Assoc | Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients [PubMed: 26374297] |
Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie | V [Ebscohost] |
Endocrinol Metab (Seoul). | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2?in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome [pmc:PMC4803547] |
Clin Pharmacol Ther.? | Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery [Pubmed:25773594] |
Lipids in Health and Disease | Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … [articles:10.1186] |
Acta Endocrinologica | SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. [jrnl:1841098] |
Biomarker for diagnosis of moyamoya disease [:] | |
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions [Pubmed: 32859455] |
chinese neurosurgical journal | Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage? [] |